Financials data is unavailable for this security.
View more
Year on year Hunan Warrant Pharmaceutical Co Ltd grew revenues 10.84% from 1.29bn to 1.43bn while net income improved 15.60% from 182.80m to 211.32m.
| Gross margin | 62.74% |
|---|---|
| Net profit margin | 13.05% |
| Operating margin | 16.06% |
| Return on assets | 8.55% |
|---|---|
| Return on equity | 11.95% |
| Return on investment | 10.16% |
More ▼
Cash flow in CNYView more
In 2023, Hunan Warrant Pharmaceutical Co Ltd increased its cash reserves by 108.20%, or 196.11m. The company earned 214.44m from its operations for a Cash Flow Margin of 14.97%. In addition the company generated 39.12m cash from investing, though they paid out 57.47m more in financing than they received.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 19.58 |
|---|---|
| Tangible book value per share | 18.44 |
More ▼
Balance sheet in CNYView more
| Current ratio | 4.25 |
|---|---|
| Quick ratio | 3.07 |
| Total debt/total equity | 0.048 |
|---|---|
| Total debt/total capital | 0.0451 |
More ▼
Growth rates in CNY
Year on year, growth in dividends per share fell -100.00% while earnings per share excluding extraordinary items rose 15.60%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.91% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 0.00% |
| EPS growth(5 years) | 19.02 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 0.3318 |
More ▼
